SCHEMBL5515673

SCHEMBL5515673

Cc1cc(C(=O)N2CCCCc3ccccc32)ccc1CNC(=O)NCC(=O)N(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
AVPR2 P30518 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6630733 0.90 AVPR2 (0.82) AVPR2
SCHEMBL5232864 0.90 AVPR2 (1.00) AVPR2
SCHEMBL5232539 0.89 AVPR2 (1.00) AVPR2
SCHEMBL5510948 0.89 AVPR2 (1.00) AVPR2
SCHEMBL6628917 0.88 AVPR2 (1.00) AVPR2
SCHEMBL5230990 0.88 AVPR2 (0.83) AVPR2
SCHEMBL5267294 0.88 AVPR2 (1.00) AVPR2
SCHEMBL6627370 0.88 AVPR2 (1.00) AVPR2
SCHEMBL6627507 0.86 AVPR2 (1.00) AVPR2
SCHEMBL6629189 0.85 AVPR2 (1.00) AVPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1226122-B1 BICYCLIC VASOPRESSIN AGONISTS FERRING BV (NL) 2004-12-15 EP claimed
US-6664249-B1 Such as 1-(4-(N-(4-methoxy-4-oxobutanoyl)aminomethyl)-3-methylbenzoyl)-2, 3,4,5-tetrahydro-1H-1-benzazepine; polyuria FERRING BV (NL) 2003-12-16 US claimed
EP-1226122-A1 BICYCLIC VASOPRESSIN AGONISTS Ferring BV (NL) 2002-07-31 EP claimed
WO-2001029005-A1 BICYCLIC VASOPRESSIN AGONISTS FERRING BV (NL) 2001-04-26 WO claimed
EP-1294698-B1 FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS FERRING BV (NL) 2007-08-01 EP disclosed
US-7176195-B2 Fused azepine derivatives and their use as antidiuretic agents FERRING BV (NL) 2007-02-13 US disclosed
US-7176195-B2 Fused azepine derivatives and their use as antidiuretic agents FERRING BV (NL) 2007-02-13 US disclosed
US-7176195-B2 Fused azepine derivatives and their use as antidiuretic agents FERRING BV (NL) 2007-02-13 US disclosed
EP-1226122-B1 BICYCLIC VASOPRESSIN AGONISTS FERRING BV (NL) 2004-12-15 EP disclosed
US-20040038962-A1 Fused azepine derivatives and their use as antidiuretic agents VANTIA LIMITED (GB) 2004-02-26 US disclosed
US-6664249-B1 Such as 1-(4-(N-(4-methoxy-4-oxobutanoyl)aminomethyl)-3-methylbenzoyl)-2, 3,4,5-tetrahydro-1H-1-benzazepine; polyuria FERRING BV (NL) 2003-12-16 US disclosed
EP-1226122-A1 BICYCLIC VASOPRESSIN AGONISTS Ferring BV (NL) 2002-07-31 EP disclosed
WO-2001029005-A1 BICYCLIC VASOPRESSIN AGONISTS FERRING BV (NL) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038962-A1 Fused azepine derivatives and their use as antidiuretic agents AVPR2, AVPR1A, AVPR1B AVPR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.